Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Bought by Two Sigma Advisers LP

Two Sigma Advisers LP boosted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 330.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 430,700 shares of the biotechnology company's stock after purchasing an additional 330,700 shares during the quarter. Two Sigma Advisers LP owned about 0.34% of Arrowhead Pharmaceuticals worth $8,097,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Avoro Capital Advisors LLC grew its stake in shares of Arrowhead Pharmaceuticals by 25.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock worth $208,889,000 after purchasing an additional 2,222,223 shares during the last quarter. Norges Bank bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $38,622,000. Farallon Capital Management LLC bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $11,821,000. Two Sigma Investments LP lifted its holdings in shares of Arrowhead Pharmaceuticals by 281.3% during the fourth quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company's stock valued at $14,934,000 after purchasing an additional 586,062 shares in the last quarter. Finally, Slate Path Capital LP lifted its stake in Arrowhead Pharmaceuticals by 7.1% during the 4th quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock valued at $98,362,000 after acquiring an additional 347,000 shares during the period. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 133,333 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the completion of the transaction, the chief executive officer now directly owns 3,773,802 shares of the company's stock, valued at $64,230,110.04. This represents a 3.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last ninety days, insiders sold 275,880 shares of company stock worth $4,034,037. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock traded up $1.49 on Thursday, hitting $17.05. 799,391 shares of the company traded hands, compared to its average volume of 1,505,253. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The stock has a market capitalization of $2.35 billion, a P/E ratio of -3.30 and a beta of 0.89. The business has a 50-day simple moving average of $13.34 and a 200 day simple moving average of $17.53. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same quarter in the previous year, the company posted ($1.02) earnings per share. Research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ARWR has been the topic of several research analyst reports. Royal Bank of Canada reissued an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Citigroup decreased their price target on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Wall Street Zen raised Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Finally, B. Riley reaffirmed a "buy" rating and issued a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.13.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.